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Abstract
BACKGROUND: Beta-blockers improve outcomes in patients with systolic heart failure. 
However, it is unknown whether their initial negative inotropic effect may increase 30-day all-
cause readmission, a target outcome for Medicare cost reduction and financial penalty for 
hospitals under the Affordable Care Act.
METHODS: Of the 3067 Medicare beneficiaries discharged alive from 106 Alabama hospitals 
(1998-2001) with a primary discharge diagnosis of heart failure and ejection fraction (EF) <45%, 
2202 were not previously on beta-blocker therapy, of which 383 received new discharge 
Corresponding author: Vikas Bhatia, MD, 1720 2nd Ave South, CH19-219, Birmingham AL 35294-2041; Telephone: 
1-205-934-9632; Fax: 1-205-975-7099; vbhatia@uabmc.edu aahmed@uab.edu. 
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
None of the authors have any conflict of interest to disclose
All authors had access to the data and a role in writing the manuscript
HHS Public Access
Author manuscript
Am J Med. Author manuscript; available in PMC 2019 September 23.
Published in final edited form as:
Am J Med. 2015 July ; 128(7): 715–721. doi:10.1016/j.amjmed.2014.11.036.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
prescriptions for beta-blockers. Propensity scores for beta-blocker use, estimated for each of the 
2202 patients, were used to assemble a matched cohort of 380 pairs of patients receiving and not 
receiving beta-blockers who were balanced on 36 baseline characteristics (mean age 73 years, 
mean EF 27%, 45% women, 33% African American)
RESULTS: Beta-blocker use was not associated with 30-day all-cause readmission (hazard ratio 
{HR}, 0.87; 95% confidence interval {CI}, 0.64-1.18) or heart failure readmission (HR, 0.95; 95% 
CI, 0.57-1.58)., but was significantly associated with lower 30-day all-cause mortality (HR, 0.29; 
95% CI, 0.12-0.73). During 4-year post-discharge, those in the beta-blocker group had lower 
mortality (HR, 0.81; 95% CI, 0.67-0.98) and combined outcome of all-cause mortality or all-cause 
readmission (HR, 0.87; 95% CI, 0.74-0.97) but not with all-cause readmission (HR, 0.89; 95% CI, 
0.76-1.04).
CONCLUSIONS: Among hospitalized older patients with systolic heart failure, discharge 
prescription of beta-blockers was associated with lower 30-day all-cause mortality and 4-year 
combined death or readmission outcomes without higher 30-day readmission.
Keywords
Systolic heart failure; Older adults; Beta blockers; Hospitalization; Readmission
Heart failure is a leading cause of hospital readmission for Medicare beneficiaries, many of 
which are considered potentially preventable.1,2 The Affordable Care Act, the new United 
States healthcare reform law, has identified 30-day all-cause readmission in hospitalized 
Medicare beneficiaries aged ≥65 years as a target outcome for reduction of Medicare costs. 
It is projected that hospitals may collectively lose about $7 billion over next 10 years for 
above-average 30-day all-cause readmission. In patients with systolic heart failure, beta-
blockers reduce mortality and hospitalization in the randomized controlled trial setting,3,4 
and their use has been associated with lower risk of one-year mortality and readmission in 
the post-discharge setting.5 However, beta-blockers have an early transient negative 
inotropic effect and concern remains that discharge initiation of these drugs in hospitalized 
patients with heart failure and reduced ejection fraction may adversely affect short-term 
outcomes and this has lately been heightened by the focus on 30-day all-cause hospital 
readmission in the Affordable Care Act. Therefore, the objective of the current study was to 
examine the association of discharge initiation of beta blockers with 30-day all-cause 
hospital readmission in hospitalized systolic heart failure patients.
MATERIALS AND METHODS
Data Source and Study Patients
We used the Alabama Heart Failure Project data for the current study, the details of which 
have been described previously.6 Briefly, medical records of fee-for-service Medicare 
beneficiaries discharged with a principal diagnosis of heart failure from 106 Alabama 
hospitals between July 1, 1998 and October 31, 2001 were identified.6–9 A diagnosis of 
heart failure was based on the International Classification of Diseases, 9th Revision, Clinical 
Modification, codes for heart failure. Copies of the 9649 charts were abstracted by trained 
technicians who directly entered data into a computer database. The 9649 hospitalizations 
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occurred in 8555 unique patients. For patients with multiple hospitalizations, charts from the 
first hospitalization were used. The selected medical records were then transferred from 
participating hospitals to the Central Clinical Data Abstraction Centers (CDAC) where 
trained technicians abstracted data from charts directly into a computer database using a data 
collection tool programmed by MedQuest Software. CDAC ensured reliability of the 
abstraction process through internal and external re-abstractions of 40 charts monthly. 
Reliability findings demonstrated agreement values >80% and Kappa values >0.60.6
New Use of Beta-Blockers: Assembly of an Inception Cohort
Of the 8555 patients, 8049 were discharged alive, of these, 5479 (68%) had data on left 
ventricular ejection fraction, of which 3067 (68%) had ejection fraction <45%. Of these 
3067 patients, 2202 (72%) were not on beta-blockers at admission. Of these, 383 (17%) 
received a discharge prescription for beta-blocker. Extensive data on baseline demographics, 
medical history including use of medications, hospital course, discharge disposition 
including medications, and physician specialty were collected.
Propensity Matching: Assembly of a Balanced Cohort
Because of the imbalances in baseline characteristics between patients receiving and not 
receiving beta-blockers (Table 1), we used propensity scores to assemble a cohort of patients 
in which those receiving and not receiving these drugs would be well-balanced on measured 
baseline characteristics.10–14 We began by estimating propensity scores or probability of 
receiving discharge prescription of beta-blockers for each of the 2202 patients using 36 
measured baseline characteristics displayed in Figure 1. Using a greedy matching protocol, 
we were able to match 380 of the 383 patients receiving beta-blockers with 380 patients not 
receiving these drugs who had similar propensity scores.15–17 We then estimated absolute 
standardized differences of the 36 measured covariates for the two treatment groups, and 
presented the percentages of pooled standard deviations as Love plots. 18–21 An absolute 
standardized difference of 0% indicates no residual bias and differences <10% are 
considered inconsequential.
Outcomes
The primary outcome of the current analysis was 30 day all-cause hospitalization. Secondary 
outcomes included all-cause mortality, heart failure hospitalizations and the combined end 
point of all-cause readmission or all-cause mortality. Time to all outcomes started from the 
date of discharge from the index hospitalization. Data on outcomes and time to events were 
obtained from the Centers for Medicare and Medicaid Services Denominator File, Medicare 
Provider Analysis and Review File and Inpatient Standard Analytical File.
Statistical Analysis
For descriptive analyses, we used Pearson Chi square and Wilcoxon rank-sum tests for 
comparisons. Kaplan-Meier plots and Cox regression analyses were used to determine the 
associations of discharge initiation of beta-blocker therapy with 30-day all-cause 
readmission. We repeated the Cox model for other outcomes at 30 days and 4 years post-
discharge. All outcomes analyses were based on matched cohort. All statistical tests were 
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two-tailed with a p-value <0.05 considered significant. Statistical analyses were performed 
using SPSS-22 for Windows (IBM Corp. 2013. IBM SPSS Statistics for Windows, Armonk, 
NY).
Results
Baseline Characteristics
Matched patients had a mean age (±SD) of 73 (±11) years, 44% were women, and 33% were 
African American. Pre-match imbalances in the distribution of age, race, history of prior 
heart failure, comorbidities and treatment between patients receiving and not receiving beta 
blockers were well-balanced after matching (Table 1 and Figure 1).
Beta-Blocker Use and 30-Day All-Cause Readmission
30-day all-cause hospital readmission occurred in 20% and 23% of matched patients 
receiving and not receiving beta-blockers, respectively (hazard ratio {HR} when beta-
blocker use is compared with their non-use, (hazard ratio {HR}, 0.87; 95% confidence 
interval {CI}, 0.64–1.18; p=0.337; Table 2). Beta-blocker use also had no association with 
heart failure readmission – occurring in 8% of matched patients receiving and not receiving 
beta-blockers, (HR 0.95; 95% CI, 0.57–1.58; Table 2).
Other Outcomes
There were only 26 (3.5%) deaths during the first 30 days of post-discharge follow-up. All-
cause mortality occurred in 2% and 5% of those receiving and not receiving beta blockers, 
respectively (HR, 0.29; 95% CI, 0.12–0.73). When stratified by EF< 20 patients, all cause 
readmission occurred in 12% vs 23% of those receiving beta blockers vs not receiving beta 
blockers,(HR,0.5;95% CI,0.20–1.24). Combined outcome of 30 day all cause readmission 
and allcause mortality occurred in 21 % and 26 % of those receiving and not receiving 
discharge prescription of beta blockers, respectively (HR, 0.81; 95% CI, 0.60–1.09; p-0.166; 
Figure 2 and Table 2). This latter association did not vary between patients with EF <20% or 
20–44%.
Beta-blocker use had no significant association with all-cause or heart failure readmission 
during 4 years post-discharge. However, there was significant reduction in both all-cause 
mortality (HR, 0.81; 95% CI, 0.67–0.98) and the combined outcome of all-cause 
readmission or all-cause mortality (HR, 0.86; 95% CI, 0.74–0.97) during 4 years after 
hospital discharge.
Discussion
Findings from the current study demonstrate that a discharge prescription for beta-blocker 
was associated with a significantly lower risk of 30-day and 4-year all-cause mortality 
without significantly increasing the risk of 30-day all-cause or heart failure readmissions. 
The use of beta-blockers was also associated with a similar lower risk of the combined end 
point of all-cause readmission or all-cause mortality at 30 days and 4 years; however, only 
the 4-year association was statistically significant, likely due to higher events. These results, 
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based on a rigorously conducted study, using an inception-cohort propensity-matched design 
suggest that hospitalized older patients with systolic heart failure may be prescribed beta-
blockers without concerns for adversely affecting 30-day all-cause readmission, an outcome 
with financial implications for nation’s hospitals.
Findings from laboratory animals and human studies suggest that beta-blockers prevent and 
reverse maladaptive ventricular remodeling in heart failure,22,23 which explain their 
beneficial effect on heart failure hospitalization and heart failure death.3,4 However, this 
effect of beta-blockers may not be apparent until after one month of therapy,24 which may in 
part explain the lack of association between beta-blocker use and lower 30-day 
readmissions. Further, the early beneficial effect of beta-blockers on disease progression and 
symptoms may also have been attenuated by the negative inotropic effects of these drugs. 
Older heart failure patients often restrict their physical activity to avoid symptoms and 
hospitalization.25 If more symptomatic patients in the non-beta-blocker group avoided 
symptoms by restricting mobility they are less likely to be readmitted, thus attenuating the 
between-group difference. However, in these same patient population, the use of digoxin and 
angiotensin-converting enzyme inhibitors or angiotensin receptor blockers was associated 
with lower readmission,17‘26 suggesting that the effect of beta-blockers on readmission 
maybe mild in hospitalized older systolic heart failure patients. Beta-blockers reduce both 
sudden cardiac death and pump failure death.3,4 The mode of death in hospitalized older 
patients with advanced systolic heart failure would be expected to be predominantly due to 
pump failure.27–31 However, because of the time-lag associated with ventricular remodeling,
24
 the lower 30-day all-cause-mortality in our study would be expected to be primarily due 
to reduction of sudden death. Given the small number of deaths during the 30-day post-
discharge period, chance remains a possibility which might have inflated the hazard ratio.
Several studies have examined the short-term effect of beta-blockers on outcomes. In the 
Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial, in clinically 
euvolemic patients with systolic heart failure, the mortality benefit of carvedilol appeared to 
begin early though it was not statistically significant, likely due to small number of events.32 
In the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With 
Heart Failure (OPTIMIZE-HF) registry, among hospitalized systolic heart failure patients, 
the use of beta-blockers was associated with an 11% (95% CI, 1%−20%) significantly lower 
all-cause readmission at one year post-discharge.5 Although data on 30-day all-cause 
readmission were not presented, the magnitude of the association between beta-blocker use 
and all-cause readmission in that study is similar to that observed in our study.
Although the use of beta-blockers in systolic heart failure has increased in recent years,5 
concerns about how their initial negative inotropic effect may adversely affect readmission 
remain a barrier to their use before hospital discharge. Due to recent focus on 30-day all-
cause readmission, hospitals and clinicians are under pressure to lower this outcome to avoid 
financial penalties, and this may further cause underutilization of these drugs during hospital 
discharge. However, findings from the current study should be reassuring. Heart failure 
patients not receiving evidence-based drugs during hospital discharge often do not receive 
them after discharge,33–35 and considering the mortality benefit of beta-blockers in older 
systolic heart failure patients, this guideline-recommended evidence-based therapy should be 
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initiated before hospital discharge to all systolic heart failure patients without an absolute 
contraindication.36 A pre-discharge (vs. post-discharge) initiation of beta-blockers has also 
been shown to be associated with higher use of beta-blockers without higher readmission.37
Our study has several limitations. Despite the use of propensity matching to assemble a 
cohort that was balanced in measured baseline characteristics, as in any observational study, 
bias due to imbalances in unmeasured covariates is possible. Lack of data on cause-specific 
deaths, invasive hemodynamic measurements, and dosage of beta-blockers used are other 
limitations. We also had no data on post-discharge use of medications, but, treatment 
crossover is likely to be minimal.33–35 Although a resultant regression dilution may 
underestimate observed associations,38 it is unlikely to explain the null association with 
readmission as there was a significant association with mortality. Chance and lower numbers 
of mortality events in 30 days could have erroneously inflated hazard ratios.Although the 
current study is based on a single state from the early 2000s, outcomes in heart failure 
patients in Alabama is similar to national estimates,1,39 and management of hospitalized 
older systolic heart failure patients has not evolved much in the past decade.
Conclusions
Among Medicare beneficiaries with heart failure and reduced ejection fraction hospitalized 
for acute decompensation, a discharge prescription for beta-blockers was associated with 
lower 30-day all-cause mortality without higher 30-day all-cause or heart failure 
readmissions suggesting that these drugs can be prescribed before hospital discharge without 
concerns for adversely affecting 30-day all-cause readmission, an outcomes of substantial 
financial consequences for nation’s hospitals.
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Clinical significance
• Beta-blocker use was associated with lower risk of 30-day all-cause mortality 
without higher 30-day all-cause or heart failure readmissions in older 
Medicare beneficiaries hospitalized for acute systolic heart failure.
• This benefit of beta-blockers was observed throughout the first 4 years after 
discharge
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Figure 1. 
Absolute standardized differences comparing 36 baseline characteristics between patients 
receiving and not receiving discharge prescription of Beta-blocker, before and after 
propensity score matching (ACE=angiotensin-converting enzyme, ARB=angiotensin 
receptor blockers, COPD=Chronic obstructive pulmonary disease)
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Figure 2. 
Kaplan-Meier plots for combined end point of 30-day all-cause readmission or all-cause 
mortality in a propensity-matched cohort of patients with heart failure and ejection fraction 
<45%, receiving and not receiving a new discharge prescription for beta-blocker 
(CI=confidence interval)
Bhatia et al. Page 11
Am J Med. Author manuscript; available in PMC 2019 September 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Bhatia et al. Page 12
Table 1
Baseline characteristics of Medicare beneficiaries hospitalized for heart failure and ejection fraction <45, not 
receiving prior betta-blocker therapy, by the receipt of a new discharge prescription for beta-blockers, before 
and after propensity score matching
Variables Mean ± SD or n (%)
Pre-match (N=2202) Post-match (N=760)
Beta blocker on discharge
P value
Beta blocker on discharge
P value
No (n=1819) Yes (n=383) No (n=380) Yes (n=380)
Age (years) 75 (±11) 73 (±11) 0.004 73 (±11) 73(±11) 0.974
Female 855 (47) 172 (45) 0.455 166 (44) 171 (45) 0.770
African American 470 (26) 126 (33) 0.005 127 (33) 125 (33) 0.939
Admission from nursing homes 83 (5) 15 (4) 0.577 13 (3) 15 (4) 0.845
Smoking 257 (14) 65 (17) 0.152 61 (16) 65 (17) 0.770
Ejection fraction (%) 28 (±9) 27 (±8) 0.008 27 (±9) 27 (±9) 0.391
Past medical history
 Prior heart failure 1367 (75) 250 (65) <0.001 250 (66) 248 (65) 0.939
 Hypertension 1204 (66) 276 (72) 0.026 273 (72) 273 (72) 1.000
 Coronary artery disease 1110 (61) 218 (57) 0.136 208 (55) 215(57) 0.661
 Prior myocardial infarction 541 (30) 97 (25) 0.940 >104 (27) 97 (26) 0.622
 Angina pectoris 222 (12) 78 (20) <0.001 69 (18) 75(20) 0.644
 Diabetes mellitus 791 (44) 181 (47) 0.177 185 (49) 179 (47) 0.717
 Percutaneous coronary intervention 253 (14) 49 (13) 0.624 40(11) 49(13) 0.367
 Coronary artery bypass surgery 538 (30) 113 (30) 1.000 105 (28) 112(30) 0.630
 Stroke 341 (19) 73 (19) 0.887 70 (18) 73 (19) 0.853
 Chronic obstructive pulmonary disease 684 (38) 113 (30) 0.003 105 (28) 113 (30) 0.575
 Dementia 158 (9) 20 (5) 0.024 16 (4) 20 (5) 0.609
 Cancer 52 (3) 10 (3) 0.790 12 (3) 10 (3) 0.829
 Atrial fibrillation 516 (28) 88 (23) 0.032 49 (23) 51 (23) 0.931
 Left bundle branch block 409 (23) 73 (19) 0.141 62 (16) 73 (19) 0.343
 Pneumonia 477 (26) 100 (26) 1.000 96 (25) 99 (26) 0.868
Clinical findings
 Pulse (beats/minute) 94 (±22) 96 (±23) 0.104 97 (±22) 97 (±24) 0.775
 Systolic blood pressure (mmHg) 144 (±30) 148 (±31) 0.056 151 (±31) 149 (±31) 0.508
 Respiration (breaths/minute) 24 (±6) 25 (±7) 0.114 24 (±6) 25 (±7) 0.605
 Pulmonary edema by chest x-ray 1305 (72) 262 (68) 0.190 266 (70) 260 (68) 0.694
Tests and procedures
 Serum creatinine (mEq/L) 1.6 (±1) 1.6 (±1) 0.819 1.7 (±1) 1.6(±1) 0.272
 Glomerular filtration rate (ml s/min/1.73m2) 54 (±24) 57 (±25) 0.047 56 (±27) 57 (±25) 0.798
In-hospital events
 Acute myocardial infarction 103 (6) 26 (7) 0.394 25 (7) 26 (7) 1.000
 Pneumonia 477 (26) 100 (26) 0.963 84 (22) 98 (26) 0.268
 Pressure ulcer 163 (9) 28 (7) 0.319 30 (8) 28 (7) 0.891
Hospital and care characteristics
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Variables Mean ± SD or n (%)
Pre-match (N=2202) Post-match (N=760)
Beta blocker on discharge
P value
Beta blocker on discharge
P value
No (n=1819) Yes (n=383) No (n=380) Yes (n=380)
 Rural hospital 410 (23) 75 (20) 0.204 78 (21) 75 (21) 0.856
 Cardiology care 1191 (66) 307 (80) <0.001 308 (81) 304 (80) 0.784
 Intensive care unit stay 75 (4) 19 (5) 0.461 17 (5) 18 (5) 1.000
 Length of stay (days) 7 (±5) 8 (±5) 0.009 8 (±7) 8 (±5) 0.929
Discharge medications
 Renin-angiotensin inhibitors 1224 (67) 286 (75) 0.005 282 (74) 283 (75) 1.000
 Digoxin 1037 (57) 221 (58) 0.803 225 (59) 218 (57) 0.670
 Loop diuretics 1567 (86) 322 (84) 0.291 317 (83) 319 (84) 0.922
 Potassium-sparing diuretics 345(19) 91 (24) 0.032 88 (23) 89 (23) 1.000
 Potassium supplement 865 (48) 144 (38) <0.001 146 (38) 143 (38) 0.881
 Hydralazine and nitrate 73 (4) 15 (4) 1.000 18 (5) 15(4) 0.722
 Antiarrhythmics 293 (16) 51 (13) 0.188 43 (11) 51 (13) 0.441
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Table 2
Association between a new discharge prescription for beta-blocker and 30-day post-discharge outcomes in a 
propensity-matched cohort of Medicare beneficiaries hospitalized for heart failure
(events)
Outcomes
New discharge prescription for beta-blocker Absolute risk 
diff.*
Hazard ratio† (95 confidence 
interval)No (n=380) %,N Yes (n=380) %,N
All-cause hospital 
readmission 23 (86) 20 (77) −3 0.87 (0.64–1.18); p=0.377
Heart failure readmission 8 (30) 8 (29)   0 0.95 (0.57–1.58); p=0.837
All-cause mortality 5(20) 2(6) −3 0.29 (0.12–0.73); p=0.008
All-cause mortality or all-
cause readmission 26 (97) 21 (81) −5 0.81 (0.60–1.09); p=0.166
*Absolute risk differences(%) were calculated by subtracting percent events in patients receiving no beta-blocker from those receiving those drugs
†
The hazard ratios compared patients receiving beta-blocker versus those not receiving beta-blocker. These hazard ratios were calculated by 
treating patients without events during the first 30 days as censored
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Table 3
Association between a new discharge prescription for beta-blocker and 4-year post-discharge outcomes in a 
propensity-matched cohort of Medicare beneficiaries hospitalized for heart failure
(events)
Outcomes
New discharge prescription for b-blocker Absolute risk diff.* Hazard ratio† (95 confidence 
interval)No (n=380) %,N Yes (n=380) %,N
All-cause hospital readmission 83 (315) 81 (309) −2 0.89 (0.76–1.04)
Heart failure readmission 49 (186) 49 (187)  0 0.92 (0.75–1.13)
All-cause mortality 60 (226) 53 (202) −7 0.81 (0.67–0.98)
All-cause mortality or all-cause 
readmission 94 (357) 89 (339) −5 0.86 (0.74–0.97)
*Absolute risk differences(%) were calculated by subtracting percent events in patients receiving no beta-blocker from those receiving those drugs
†
The hazard ratios compared patients receiving beta-blocker versus those not receiving beta-blocker. These hazard ratios were calculated by 
treating patients without events during the first 30 days as censored
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